Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: A controlled phase 2B trial

The Lancet Oncology

Volumn 12, Issue 12, 2011, Pages 1125-1133

  Quoix, Elisabeth ^a   Ramlau, Rodryg ^b   Westeel, Virginie ^c   Papai, Zsolt ^d   Madroszyk, Anne ^e   Riviere, Alain ^f   Koralewski, Piotr ^g   Breton, Jean Luc ^h   Stoelben, Erich ⁱ   Braun, Denis ^j   Debieuvre, Didier ^k   Lena, Hervé ^l   Buyse, Marc ^m   Chenard, Marie Pierre ⁿ   Acres, Bruce ^o   Lacoste, Gisèle ^o   Bastien, Bérangère ^o   Tavernaro, Annette ^o   Bizouarne, Nadine ^o   Bonnefoy, Jean Yves ^o   Limacher, Jean Marc ^o   more..

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b Wielkoposkie Centrum   (Poland)

^c UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^d Fejér Megyei Szent György Kórház ^*  (Hungary)

^e INSTITUT PAOLI CALMETTES   (France)

^f Centre de Lutte Contre le Cancer François Baclesse   (France)

^g Wojewodzski Szpital Specjalistyczny   (Poland)

^h Centre Hospitalier de Belfort Montbeliard   (France)

ⁱ Kliniken der Stadt Koln GmbH   (Germany)

^j Centre Hospitalier de Briey   (France)

^k Centre Hospitalier Intercommunal de Haute Saône   (France)

^l PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^m INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

ⁿ HÔPITAL DE HAUTEPIERRE   (France)

^o TRANSGENE S A   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CISPLATIN; GEMCITABINE; INTERLEUKIN 2; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; MUCIN 1; TG 4010; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEART LEFT VENTRICLE FAILURE; HUMAN; IMMUNOHISTOCHEMISTRY; INJECTION SITE PAIN; INJECTION SITE REACTION; INTENTION TO TREAT ANALYSIS; KARNOFSKY PERFORMANCE STATUS; LUNG EDEMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PLEURA EMPYEMA; PNEUMONIA; PNEUMOTHORAX; POXVIRUS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; VACCINIA VIRUS; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; HUMANS; INTERLEUKIN-2; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MUCIN-1; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 81255127285     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70259-5     Document Type: Article

References (28)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Ramalingam S, Belani C Systemic chemotherapy for advanced NSCLC: recent advances and future directions. Oncologist 2008, 13:5-13.
3. Azzoli CG, Baker S, Temin S, et al. American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
4. Vansteenkiste J, Zielinski M, Linder A, et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2007, 25(suppl 18). abstr 7554.
5. Butts C, Maksymiuk A, Goss G, et al. A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis [abstract B1-01]. J Thorac Oncol 2007, 2(suppl 4):332-333.
6. Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006, 24:4721-4730.
7. Digumarti R, Wang Y, Raman G, et al. A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer. J Thorac Oncol 2011, 6:1098-1103.
8. Cohen S, Kaufman HL TG-4010 Transgene. Curr Opin Investig Drugs 2004, 5:1319-1328.
9. Ramlau R, Quoix E, Rolski J, et al. A phase II study of TG4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J Thorac Oncol 2008, 3:735-744.
10. Sobin LH, Wittekind C International Union Against Cancer (UICC) TNM classification of malignant tumors 2002, Wiley-Liss, New York. 6th edn.
11. Miller AB, Hoogstraten B, Staquet M, Winkler A Reporting results of cancer treatment. Cancer 1981, 47:207-214.
12. E6 (R1). Good clinical practice: consolidated guideline ICH Efficacy Guidelines, (accessed Oct 12, 2011). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf.
13. Pocock SJ, Simon R Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials. Biometrics 1975, 31:103-105.
14. Freedman LS, White SJ On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial. Biometrics 1976, 32:691-694.
15. Common Terminology Criteria for Adverse Events (CTCAE) v3.0 National Cancer Institute, (accessed Oct 12, 2011). http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf.
16. Fleming TR One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982, 38:143-151.
17. Brookmeyer R, Crowley J A confidence interval for the median survival time. Biometrics 2007, 39:29-41.
18. Hareuveni M, Tsarfaty I, Zaretsky J, et al. A transcribed gene, containing a variable number of tandem repeats, codes for a human epithelial tumor antigen. Eur J Biochem 1990, 189:475-486.
19. Jarrad JA MUC1 is a novel marker for type II pneumocyte lineage during lung carcinogenesis. Canc Res 1998, 58:5582-5589.
20. Ho SB, Niehans GA, Lyftog C, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993, 53:641-651.
21. Burchell J, Gendler S, Taylor-Papadimitriou J, et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 1987, 47:5476-5482.
22. Vollmar J, Arndtz N, Eckl KM, et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 2006, 42:2065-2076.
23. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
24. Somaiah N, Simon GR Molecular targeted and biologic therapies for non-small cell lung cancer. J Thorac Oncol 2010, 5(suppl 6):434-454.
25. Vivier E, Tomaselo E, Baratin M, Walzer T, Ugolini S Functions of natural killer cells. Nat Immunol 2008, 9:503-510.
26. Vivier E, Ugolini S Regulatory natural killer cells: new players in the IL-10 anti-inflammatory response. Cell Host Microbe 2009, 6:493-495.
27. Amato RJ, Hawkins RE, Kaufman HL, et al. Vaccination of metastatic renal cancer patients with MVA-5T4 (TroVax): a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res 2010, 16:5539-5547.
28. Small E, Demkow T, Gerritsen WR, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). 2009 Genitourinary Cancers Symposium; Orlando, FL, USA; Feb 26-28. Abstract 7.